FDA extends approval for GSK’s RSV vaccine, AREXVY, to adults aged 50-59 at increased risk
The U.S. Food and Drug Administration (FDA) has officially broadened the age indication for GSK plc’s (LSE/NYSE: GSK) AREXVY, marking it as the first adjuvanted Respiratory Syncytial Virus (RSV) vaccine authorized for adults aged 50-59 who are at heightened risk of severe outcomes from the virus. This extension builds on the existing approval for individuals […]